| Chelsea Suzanne Shelman, PHARMD | |
|
7377 Alcoa Rd, Bryant, AR 72022-6204 | |
| (501) 776-4361 | |
| (501) 776-4371 |
| Full Name | Chelsea Suzanne Shelman |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 7377 Alcoa Rd, Bryant, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1649525775 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PD11918 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Chelsea Suzanne Shelman, PHARMD 7377 Alcoa Rd, Bryant, AR 72022-6204 Ph: () - | Chelsea Suzanne Shelman, PHARMD 7377 Alcoa Rd, Bryant, AR 72022-6204 Ph: (501) 776-4361 |
News Archive
Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Nitrofurantoin Oral Suspension in the 25 mg/5 ml strength effective May 13, 2011. Amneal's generic, the first on the market, is an AA-rated, therapeutically equivalent alternative to Furadantin.
Aptuit, Inc., and Siena Biotech S.p.A., today announced a strategic partnership in which Siena Biotech will take a minority stake in Aptuit's Italian operations in Verona, Italy, and Aptuit will become a provider of choice for Siena Biotech's development pipeline. Under the agreement Aptuit and Siena Biotech will work collaboratively on the development of Siena Biotech's pipeline of compounds, focused in three key therapeutic areas, including Alzheimer's disease, Huntington's disease and oncology.
A clinical trial involving 5,045 women in South Africa and Zimbabwe found no statistical difference in the rate of new HIV infections in the two study arms: those who received a diaphragm plus lubricant along with male condoms for their partners and those who only received male condoms.
Traditionally, both air and tap water have been used as oral contrast agents to achieve adequate gastric distension for preoperative computed tomography imaging in patients with early gastric cancer.
VBL Therapeutics today announced positive preclinical results evaluating VB-201 for the treatment of psoriasis. VB-201 is a first-in-class, orally administered immune response modifier expected to reduce inflammation by targeting key pro-inflammatory cytokines. Today's data suggest that VB-201 has significant anti-inflammatory properties that are active against psoriasis; an ongoing Phase 2 efficacy and safety study is currently evaluating VB-201 for the treatment of patients with psoriasis.
› Verified 6 days ago
Me-kyoung Choi, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3220 N Reynolds Rd, Bryant, AR 72022 Phone: 501-847-0803 | |
Sheree Mcconkey, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 304 Monticello W, Bryant, AR 72022 Phone: 501-847-6620 | |
Keri Stuff, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5500 Highway 5 N, Bryant, AR 72022 Phone: 501-847-7420 | |
Jeffrey Reagan Limbaugh Snow, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3801 Highway 5 N, Bryant, AR 72022 Phone: 501-847-2880 | |
Jamie Bourland, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 7377 Alcoa Rd, Bryant, AR 72022 Phone: 501-620-0334 | |
D'lisa Renee Haas, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5500 Highway 5 N, Bryant, AR 72022 Phone: 501-847-7420 | |
Benjamin Ramsey, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2203 N Reynolds Rd, Bryant, AR 72022 Phone: 501-481-8964 |